Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | STK39 | Q9UEW8 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29015520 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1RAB9AKMOHDAC8 | |
| SCHEMBL30396850 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1RAB9AKMOHDAC8 | |
| SCHEMBL20536246 | 0.91 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1RAB9AKMOHDAC8 | |
| SCHEMBL20536245 | 0.91 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1RAB9AKMOHDAC8 | |
| SCHEMBL29015479 | 0.91 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1RAB9AKMOHDAC8 | |
| SCHEMBL29015530 | 0.89 | KMO (0.39) | KMOHDAC8HDAC1HDAC6PGR | |
| SCHEMBL30396183 | 0.85 | ALDH1A1 (0.42) | SMN1; SMN2NPC1RAB9AHDAC8HDAC1 | |
| SCHEMBL20535655 | 0.84 | HDAC8 (0.40) | SMN1; SMN2NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL20535659 | 0.84 | HDAC8 (0.40) | SMN1; SMN2NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL23709920 | 0.84 | NPC1 (0.37) | SMN1; SMN2NPC1RAB9AHDAC8HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | SMN1; SMN2 239/4885NPC1 34/4885RAB9A 347/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | SMN1; SMN2 239/4885NPC1 34/4885RAB9A 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.